gamma-aminobutyric acid has been researched along with Neuralgia, Sciatic in 25 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study will establish the efficacy of pregabalin in reducing leg pain intensity in patients with sciatica and provide important information regarding the effect of pregabalin treatment on disability and quality of life." | 9.17 | PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. ( Billot, L; Day, RO; Hancock, MJ; Harris, I; Jan, S; Koes, BW; Latimer, J; Lin, CW; Maher, CG; Mathieson, S; McLachlan, AJ; Pik, J, 2013) |
| "This study compared the effects of pregabalin (300 mg) and the tetracycline antibiotic and glial attenuator minocycline (400 mg) on capsaicin-induced spontaneous pain, flare, allodynia and hyperalgesia in patients with unilateral sciatica on both their affected and unaffected leg." | 9.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "Patients with unilateral sciatica have heightened responses to intradermal capsaicin compared to pain-free volunteers." | 9.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "It cannot be concluded that minocycline is unsuitable for further evaluation as an anti-neuropathic pain drug as pregabalin, our positive control, failed to reduce capsaicin-induced neuropathic pain." | 9.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear." | 8.93 | Pregabalin and gabapentin for the treatment of sciatica. ( Marshman, LA; Plummer, D; Robertson, K, 2016) |
| "We describe a 60-year-old woman who became comatose after a single dose of gabapentin for right-sided sciatalgia." | 7.73 | Gabapentin-induced coma in a patient with renal failure. ( Aygen, B; Bektas, S; Berilgen, MS; Dag, S; Dogukan, A; Gunal, AI, 2006) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| " The medicine dosage will be titrated up to the participant's optimal dose, to a maximum 600 mg per day." | 6.78 | PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. ( Billot, L; Day, RO; Hancock, MJ; Harris, I; Jan, S; Koes, BW; Latimer, J; Lin, CW; Maher, CG; Mathieson, S; McLachlan, AJ; Pik, J, 2013) |
| "Sciatica is a type of neuropathic pain that is characterised by pain radiating into the leg." | 6.78 | PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. ( Billot, L; Day, RO; Hancock, MJ; Harris, I; Jan, S; Koes, BW; Latimer, J; Lin, CW; Maher, CG; Mathieson, S; McLachlan, AJ; Pik, J, 2013) |
| "Gabapentin has been approved in the United States for the treatment of epilepsy and postherpetic neuralgia." | 5.35 | Gabapentin as a potential option for treatment of sciatica. ( Grice, GR; Mertens, MK, 2008) |
| "This study will establish the efficacy of pregabalin in reducing leg pain intensity in patients with sciatica and provide important information regarding the effect of pregabalin treatment on disability and quality of life." | 5.17 | PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. ( Billot, L; Day, RO; Hancock, MJ; Harris, I; Jan, S; Koes, BW; Latimer, J; Lin, CW; Maher, CG; Mathieson, S; McLachlan, AJ; Pik, J, 2013) |
| "This study compared the effects of pregabalin (300 mg) and the tetracycline antibiotic and glial attenuator minocycline (400 mg) on capsaicin-induced spontaneous pain, flare, allodynia and hyperalgesia in patients with unilateral sciatica on both their affected and unaffected leg." | 5.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "Patients with unilateral sciatica have heightened responses to intradermal capsaicin compared to pain-free volunteers." | 5.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "It cannot be concluded that minocycline is unsuitable for further evaluation as an anti-neuropathic pain drug as pregabalin, our positive control, failed to reduce capsaicin-induced neuropathic pain." | 5.16 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica. ( Briggs, N; Gentgall, M; Hutchinson, MR; Rolan, P; Sumracki, NM; Williams, DB, 2012) |
| "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear." | 4.93 | Pregabalin and gabapentin for the treatment of sciatica. ( Marshman, LA; Plummer, D; Robertson, K, 2016) |
| "We describe a 60-year-old woman who became comatose after a single dose of gabapentin for right-sided sciatalgia." | 3.73 | Gabapentin-induced coma in a patient with renal failure. ( Aygen, B; Bektas, S; Berilgen, MS; Dag, S; Dogukan, A; Gunal, AI, 2006) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| " The medicine dosage will be titrated up to the participant's optimal dose, to a maximum 600 mg per day." | 2.78 | PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. ( Billot, L; Day, RO; Hancock, MJ; Harris, I; Jan, S; Koes, BW; Latimer, J; Lin, CW; Maher, CG; Mathieson, S; McLachlan, AJ; Pik, J, 2013) |
| "Sciatica is a type of neuropathic pain that is characterised by pain radiating into the leg." | 2.78 | PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. ( Billot, L; Day, RO; Hancock, MJ; Harris, I; Jan, S; Koes, BW; Latimer, J; Lin, CW; Maher, CG; Mathieson, S; McLachlan, AJ; Pik, J, 2013) |
| "MCS reversed the hyperalgesia induced by peripheral neuropathy in the rats with chronic sciatic nerve constriction and induced a significant increase in the glycine and GABA levels in the PAG in comparison with the naive and sham-treated rats." | 1.51 | Neurochemical effects of motor cortex stimulation in the periaqueductal gray during neuropathic pain. ( Antunes, GF; Assis, DV; Auada, AVV; de Andrade, EM; Fonoff, ET; Gouveia, FV; Lebrun, I; Lopes, PSS; Martinez, RCR; Pagano, RL, 2019) |
| " In this study, we tested the hypothesis that HIV gp120 combined with antiretroviral therapy reduces spinal GABAergic inhibitory tone and that restoration of GABAergic inhibitory tone will reduce HIV-related NP in a rat model." | 1.42 | Gene Transfer of Glutamic Acid Decarboxylase 67 by Herpes Simplex Virus Vectors Suppresses Neuropathic Pain Induced by Human Immunodeficiency Virus gp120 Combined with ddC in Rats. ( Candiotti, KA; Hao, S; Huang, W; Kanao, M; Kanda, H; Levitt, RC; Liu, S; Lubarsky, DA; Yi, H, 2015) |
| "Adenosine is an inhibitory neuromodulator that was previously thought to mediate antinociception through the A1 and A2A receptor subtypes." | 1.42 | Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. ( Castonguay, A; Chen, Z; Cottet, M; De Koninck, Y; Doyle, T; Egan, TM; Ford, A; Jacobson, KA; Little, JW; Salvemini, D; Symons-Liguori, AM; Tosh, DK; Vanderah, TW, 2015) |
| "NPC-treated animals showed decreased hyperalgesia and allodynia 1-3week post-transplantation; vehicle-injected CCI rats continued displaying pain behaviors." | 1.38 | Intraspinal transplantation of GABAergic neural progenitors attenuates neuropathic pain in rats: a pharmacologic and neurophysiological evaluation. ( Gajavelli, S; Hentall, ID; Jergova, S; Sagen, J; Varghese, MS, 2012) |
| "Gabapentin has been approved in the United States for the treatment of epilepsy and postherpetic neuralgia." | 1.35 | Gabapentin as a potential option for treatment of sciatica. ( Grice, GR; Mertens, MK, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attal, N | 1 |
| Barrot, M | 1 |
| Maher, CG | 2 |
| Lin, CWC | 1 |
| Mathieson, S | 2 |
| Kosugi, K | 1 |
| Tagami, K | 1 |
| Tanimoto, T | 1 |
| Figueiredo, EG | 1 |
| Teixeira, MJ | 1 |
| Bingel, U | 1 |
| de Andrade, EM | 1 |
| Martinez, RCR | 1 |
| Pagano, RL | 1 |
| Lopes, PSS | 1 |
| Auada, AVV | 1 |
| Gouveia, FV | 1 |
| Antunes, GF | 1 |
| Assis, DV | 1 |
| Lebrun, I | 1 |
| Fonoff, ET | 1 |
| McLachlan, AJ | 1 |
| Latimer, J | 1 |
| Koes, BW | 1 |
| Hancock, MJ | 1 |
| Harris, I | 1 |
| Day, RO | 1 |
| Pik, J | 1 |
| Jan, S | 1 |
| Billot, L | 1 |
| Lin, CW | 1 |
| Gialanella, B | 1 |
| Prometti, P | 1 |
| Ferlucci, C | 1 |
| Hirsch, S | 1 |
| Dickenson, A | 1 |
| Corradini, L | 1 |
| Kanao, M | 1 |
| Kanda, H | 1 |
| Huang, W | 1 |
| Liu, S | 1 |
| Yi, H | 1 |
| Candiotti, KA | 1 |
| Lubarsky, DA | 1 |
| Levitt, RC | 1 |
| Hao, S | 1 |
| Ford, A | 1 |
| Castonguay, A | 1 |
| Cottet, M | 1 |
| Little, JW | 1 |
| Chen, Z | 1 |
| Symons-Liguori, AM | 1 |
| Doyle, T | 1 |
| Egan, TM | 1 |
| Vanderah, TW | 1 |
| De Koninck, Y | 1 |
| Tosh, DK | 1 |
| Jacobson, KA | 1 |
| Salvemini, D | 1 |
| Robertson, K | 1 |
| Marshman, LA | 2 |
| Plummer, D | 1 |
| Robertson, KL | 1 |
| Watson, CJ | 1 |
| Schmidtko, A | 1 |
| Luo, C | 1 |
| Gao, W | 1 |
| Geisslinger, G | 1 |
| Kuner, R | 1 |
| Tegeder, I | 1 |
| Kara, M | 1 |
| Ozçakar, L | 1 |
| Eken, G | 1 |
| Ozen, G | 1 |
| Kiraz, S | 1 |
| Kumar, N | 1 |
| Laferriere, A | 1 |
| Yu, JS | 1 |
| Leavitt, A | 1 |
| Coderre, TJ | 1 |
| Jergova, S | 1 |
| Hentall, ID | 1 |
| Gajavelli, S | 1 |
| Varghese, MS | 1 |
| Sagen, J | 1 |
| Sumracki, NM | 1 |
| Hutchinson, MR | 1 |
| Gentgall, M | 1 |
| Briggs, N | 1 |
| Williams, DB | 1 |
| Rolan, P | 1 |
| Moore, KA | 1 |
| Kohno, T | 1 |
| Karchewski, LA | 1 |
| Scholz, J | 1 |
| Baba, H | 1 |
| Woolf, CJ | 1 |
| Rashid, MH | 1 |
| Ueda, H | 1 |
| Kassuya, CA | 1 |
| Silvestre, AA | 1 |
| Rehder, VL | 1 |
| Calixto, JB | 1 |
| Dogukan, A | 1 |
| Aygen, B | 1 |
| Berilgen, MS | 1 |
| Dag, S | 1 |
| Bektas, S | 1 |
| Gunal, AI | 1 |
| Narita, M | 2 |
| Nakajima, M | 1 |
| Miyoshi, K | 1 |
| Nagumo, Y | 1 |
| Miyatake, M | 1 |
| Yajima, Y | 1 |
| Yanagida, K | 1 |
| Yamazaki, M | 1 |
| Suzuki, T | 1 |
| Grice, GR | 1 |
| Mertens, MK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Minocycline on Neuropathic Pain[NCT01869907] | Phase 4 | 60 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gamma-aminobutyric acid and Neuralgia, Sciatic
| Article | Year |
|---|---|
Pregabalin and gabapentin for the treatment of sciatica.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2016 |
3 trials available for gamma-aminobutyric acid and Neuralgia, Sciatic
| Article | Year |
|---|---|
PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial.
Topics: Analgesics; Clinical Protocols; Combined Modality Therapy; Cost-Benefit Analysis; Disability Evaluat | 2013 |
Gabapentin Superadded to a Pre-Existent Regime Containing Amytriptyline for Chronic Sciatica.
Topics: Adult; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Chronic Disease; Cohort Studies; | 2016 |
The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica.
Topics: Adult; Analysis of Variance; Capsaicin; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combi | 2012 |
21 other studies available for gamma-aminobutyric acid and Neuralgia, Sciatic
| Article | Year |
|---|---|
Is Pregabalin Ineffective in Acute or Chronic Sciatica?
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pregabalin; Sciatica | 2017 |
Trial of Pregabalin for Acute and Chronic Sciatica.
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pain Measurement; Pregabalin; Sciatica; Treatment Outco | 2017 |
Trial of Pregabalin for Acute and Chronic Sciatica.
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pain Measurement; Pregabalin; Sciatica; Treatment Outco | 2017 |
Trial of Pregabalin for Acute and Chronic Sciatica
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pain Measurement; Pregabalin; Sciatica; Treatment Outco | 2017 |
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Pregabalin; Sciatica | 2017 |
Neurochemical effects of motor cortex stimulation in the periaqueductal gray during neuropathic pain.
Topics: Analgesia; Animals; Bicuculline; Deep Brain Stimulation; Efferent Pathways; GABA Antagonists; gamma- | 2019 |
Low back pain radiating to the leg: an atypical cause.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclohexanecarbox | 2013 |
Anesthesia influences neuronal activity and drug effectiveness in neuropathic rats.
Topics: Action Potentials; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2014 |
Gene Transfer of Glutamic Acid Decarboxylase 67 by Herpes Simplex Virus Vectors Suppresses Neuropathic Pain Induced by Human Immunodeficiency Virus gp120 Combined with ddC in Rats.
Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Cyclic AMP Response Element-Binding Protein; Decarboxy | 2015 |
Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Analgesics; Animals; Disease Models, Animal; Dose-Respons | 2015 |
Insular balance of glutamatergic and GABAergic signaling modulates pain processing.
Topics: Analysis of Variance; Animals; Avoidance Learning; Cerebral Cortex; Disease Models, Animal; Excitato | 2016 |
Genetic deletion of synapsin II reduces neuropathic pain due to reduced glutamate but increased GABA in the spinal cord dorsal horn.
Topics: Activating Transcription Factor 3; Adenosine Triphosphate; Afferent Pathways; Animals; Calcium Signa | 2008 |
Deep venous thrombosis and inferior vena cava agenesis causing double crush sciatic neuropathy in Behçet's disease.
Topics: Adolescent; Amines; Behcet Syndrome; Colchicine; Cyclohexanecarboxylic Acids; Drug Therapy, Combinat | 2008 |
Evidence that pregabalin reduces neuropathic pain by inhibiting the spinal release of glutamate.
Topics: Analgesics; Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Rel | 2010 |
Intraspinal transplantation of GABAergic neural progenitors attenuates neuropathic pain in rats: a pharmacologic and neurophysiological evaluation.
Topics: Action Potentials; Analysis of Variance; Animals; Disease Models, Animal; Embryo, Mammalian; Embryon | 2012 |
Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord.
Topics: Animals; Blotting, Western; Cell Death; Disease Models, Animal; Excitatory Postsynaptic Potentials; | 2002 |
Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism.
Topics: Analgesics; Animals; Bridged Bicyclo Compounds, Heterocyclic; gamma-Aminobutyric Acid; Hyperalgesia; | 2002 |
Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Edema; | 2003 |
Gabapentin-induced coma in a patient with renal failure.
Topics: Administration, Oral; Amines; Coma; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; F | 2006 |
Role of spinal voltage-dependent calcium channel alpha 2 delta-1 subunit in the expression of a neuropathic pain-like state in mice.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cells, Cultured; Cyclohexanecarboxylic Acids; Disease | 2007 |
Gabapentin as a potential option for treatment of sciatica.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2008 |